Perkin-Elmer
This article was originally published in The Gray Sheet
Executive Summary
Firm plans to spin out shares through a tax-free stock distribution of its newly created Celera Genomics business subject to shareholder and final board approval, the firm announces Sept. 23. Celera is an 80/20 joint venture between Perkin-Elmer and The Institute for Genomic Research which is mounting a private sector effort to sequence the human genome in three years